Brokerages Set Evolus, Inc. (NASDAQ:EOLS) Price Target at $21.25

Evolus, Inc. (NASDAQ:EOLS) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $21.25.

Several research analysts have recently commented on EOLS shares. HC Wainwright reduced their target price on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC reiterated a “hold” rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. BTIG Research reduced their target price on Evolus from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded Evolus from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th.

Evolus Stock Performance

Shares of NASDAQ EOLS opened at $7.66 on Wednesday. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00. Evolus has a 12 month low of $5.71 and a 12 month high of $17.82. The stock has a 50 day moving average of $8.26 and a 200-day moving average of $10.19. The company has a market capitalization of $495.45 million, a P/E ratio of -7.82 and a beta of 1.07.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 16,582 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.89, for a total value of $163,995.98. Following the completion of the sale, the insider directly owned 364,927 shares in the company, valued at $3,609,128.03. The trade was a 4.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the sale, the chief marketing officer owned 89,949 shares of the company’s stock, valued at $675,516.99. This trade represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 133,627 shares of company stock valued at $1,325,764. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Evolus

Several institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC boosted its stake in Evolus by 830.2% in the 2nd quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock valued at $974,000 after purchasing an additional 94,423 shares during the period. Caxton Associates LLP bought a new stake in Evolus in the 2nd quarter valued at $148,000. Tower Research Capital LLC TRC boosted its stake in Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after purchasing an additional 5,691 shares during the period. Soleus Capital Management L.P. boosted its stake in Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after purchasing an additional 1,039,842 shares during the period. Finally, Man Group plc boosted its stake in Evolus by 23.5% in the 2nd quarter. Man Group plc now owns 125,749 shares of the company’s stock valued at $1,158,000 after purchasing an additional 23,922 shares during the period. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.